11.29
-0.12 (-1.05%)
Market Trend
Short Term | Medium Term | ||
Industry | Biotechnology (US) | Mixed | Bearish |
Biotechnology (Global) | Mixed | Bearish | |
Stock | Neumora Therapeutics, Inc. | Bearish | - |
Stockmoo Score
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts. |
|
Sector | Healthcare |
Industry | Biotechnology |
Ownership
Name | Date | Shares Held |
---|---|---|
Mic Capital Management Uk Llp | 30 Jun 2024 | 4,460,700 |
52 Weeks Range | ||
Price Target Range | ||
High | 29.00 (RBC Capital, 156.86%) | Buy |
Median | 23.00 (103.72%) | |
Low | 20.00 (Mizuho, 77.15%) | Buy |
Average | 24.00 (112.58%) | |
Total | 3 Buy | |
Avg. Price @ Call | 11.06 |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
Needham | 12 Sep 2024 | 23.00 (103.72%) | Buy | 11.83 |
22 Jul 2024 | 23.00 (103.72%) | Buy | 11.61 | |
RBC Capital | 04 Sep 2024 | 29.00 (156.86%) | Buy | 10.99 |
Mizuho | 08 Jul 2024 | 20.00 (77.15%) | Buy | 10.35 |
Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
---|---|---|---|---|
LENZ ROBERT A. | - | 11.83 | -32,948 | -389,775 |
Aggregate Net Quantity | -32,948 | |||
Aggregate Net Value ($) | -389,775 | |||
Aggregate Avg. Buy ($) | - | |||
Aggregate Avg. Sell ($) | 11.83 |
Name | Holder | Date | Type | Quantity | Price | Value ($) |
---|---|---|---|---|---|---|
LENZ ROBERT A. | Officer | 12 Sep 2024 | Automatic sell (-) | 32,948 | 11.83 | 389,775 |
Date | Type | Details |
---|---|---|
14 Aug 2024 | Announcement | Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders |
06 Aug 2024 | Announcement | Neumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update |
20 Jun 2024 | Announcement | Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer’s Disease Agitation |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2024 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |